For example, although frequently mutated in 5–20% of PCa, the p53 status also failed to serve as a prognostic marker for survival in localized prostate adenocarcinoma while it serves as a useful marker in locally advanced PCa treated by androgen deprivation 25–27. This evidence concerns the gene TP53 and posterior cortical atrophy.